A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Denosumab (Primary)
- Indications Bone resorption; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 01 Nov 2021 Results (n=740) of pooled analysis from SPLENDOUR and AMGEN-249; assessing potential anti-tumour effect and subsequent OS impact of denosumab in NSCLC and assessing efficacy in term of OS and progression-free survival in the combined data sets, published in the Lung Cancer
- 07 Dec 2018 Results published in the European Clinical Trials Database Trial Registry.
- 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics